Skip to content
Home/Companies/Biotech/Vantage Biosciences
Vantage Biosciences

Vantage Biosciences

Biotech·UK·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns Vantage Biosciences?

Vantage Biosciences is currently owned by ALSA Ventures through ALSA Ventures European Biotechnology Fund (2020 vintage), since 2023.

Hand-verified · updated 2026-05-22

ALSA Ventures
Investor
ALSA Ventures
ALSA Ventures European Biotechnology Fund · 2020 · Life Sciences VC

Key facts

HQUK
SectorBiotech
StatusActive
Websitewww.vantage-biosciences.com

More from ALSA Ventures European Biotechnology Fund

Other portfolio companies in the same fund.

ReproNovo
Active
BiotechSwitzerland· 2025
Axovia Therapeutics
Axovia Therapeutics
Active
BiotechUK· 2023
Promatix
Active
BiotechUK· 2021
Montis Biosciences
Montis Biosciences
Active
BiotechBelgium· 2020
Epsilogen
Epsilogen
Active
BiotechUK· 2018

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Vantage Biosciences

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Vantage Biosciences.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue